The results were recently confirmed in the adult NPM1-mutated (mut) AML population from the AMLSG 09-09 phase III study, which compared the clinical outcome of patients receiving GO plus induction (3 mg/mq on day 1) and consolidation chemotherapy (3 mg/mq on day 1 of the first consolidation cycle) [83]. The gene discussed is NPM1; the disease is acute myeloid leukemia.